company background image
LGVN

Longeveron NasdaqCM:LGVN Stock Report

Last Price

US$4.04

Market Cap

US$84.8m

7D

-11.4%

1Y

9.2%

Updated

23 Sep, 2022

Data

Company Financials +
LGVN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

LGVN Stock Overview

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions.

Longeveron Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Longeveron
Historical stock prices
Current Share PriceUS$4.04
52 Week HighUS$45.00
52 Week LowUS$2.84
Beta0
1 Month Change-22.31%
3 Month Change-40.50%
1 Year Change9.19%
3 Year Changen/a
5 Year Changen/a
Change since IPO-45.48%

Recent News & Updates

Aug 31

Longeveron spikes after FDA’s Fast Track Designation for lead candidate

The shares of clinical-stage biotech Longeveron Inc. (NASDAQ:LGVN) jumped in the pre-market trading Wednesday after the company announced that the FDA issued Fast Track Designation for its lead asset Lomecel-B as a treatment for Hypoplastic Left Heart Syndrome (HLHS). A rare congenital cardiac defect impacting heart’s ability to pump blood, HLHS affects an estimated ~1,000 babies per year in the U.S. The FDA offers the Fast Track designation to accelerate the development and review of drugs targeted at serious conditions with unmet medical needs. It allows developers to communicate frequently with the regulator on plans for clinical studies. If certain criteria are met, such programs will also be able to win the Accelerated Approval and Priority Review, enabling them to reach patients sooner. A cell-based therapeutic candidate, Lomecel-B, is currently undergoing a Phase 2a randomized clinical trial involving 38 patients. In December, LGVN shares surged after the company announced FDA’s orphan drug designation for Lomecel-B in HLHS.

Jul 15
Is Longeveron (NASDAQ:LGVN) In A Good Position To Invest In Growth?

Is Longeveron (NASDAQ:LGVN) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Shareholder Returns

LGVNUS BiotechsUS Market
7D-11.4%-5.0%-5.2%
1Y9.2%-30.0%-23.1%

Return vs Industry: LGVN exceeded the US Biotechs industry which returned -30.9% over the past year.

Return vs Market: LGVN exceeded the US Market which returned -21.6% over the past year.

Price Volatility

Is LGVN's price volatile compared to industry and market?
LGVN volatility
LGVN Average Weekly Movement10.6%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.9%
10% least volatile stocks in US Market2.8%

Stable Share Price: LGVN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: LGVN's weekly volatility has decreased from 45% to 11% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201419Chris Minhttps://www.longeveron.com

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company’s lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer’s disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome.

Longeveron Fundamentals Summary

How do Longeveron's earnings and revenue compare to its market cap?
LGVN fundamental statistics
Market CapUS$84.79m
Earnings (TTM)-US$18.06m
Revenue (TTM)US$1.28m

66.4x

P/S Ratio

-4.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LGVN income statement (TTM)
RevenueUS$1.28m
Cost of RevenueUS$584.00k
Gross ProfitUS$693.00k
Other ExpensesUS$18.75m
Earnings-US$18.06m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.86
Gross Margin54.27%
Net Profit Margin-1,414.10%
Debt/Equity Ratio0%

How did LGVN perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is LGVN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LGVN?

Other financial metrics that can be useful for relative valuation.

LGVN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue47.5x
Enterprise Value/EBITDA-3.9x
PEG Ration/a

Price to Book Ratio vs Peers

How does LGVN's PB Ratio compare to its peers?

LGVN PB Ratio vs Peers
The above table shows the PB ratio for LGVN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average0.8x
CADL Candel Therapeutics
1.6x-25.2%US$96.2m
MGTA Magenta Therapeutics
0.6x-7.6%US$82.4m
BDTX Black Diamond Therapeutics
0.5x-8.8%US$71.2m
EPIX ESSA Pharma
0.4x-18.1%US$77.1m
LGVN Longeveron
2.9x-25.9%US$84.8m

Price-To-Book vs Peers: LGVN is expensive based on its Price-To-Book Ratio (2.9x) compared to the peer average (0.8x).


Price to Earnings Ratio vs Industry

How does LGVN's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: LGVN is expensive based on its Price-To-Book Ratio (2.9x) compared to the US Biotechs industry average (1.6x)


Price to Book Ratio vs Fair Ratio

What is LGVN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LGVN PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate LGVN's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of LGVN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate LGVN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LGVN's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Longeveron forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-25.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: LGVN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LGVN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LGVN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: LGVN's revenue is expected to decline over the next 3 years (-45.5% per year).

High Growth Revenue: LGVN's revenue is forecast to decline over the next 3 years (-45.5% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if LGVN's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Longeveron performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-45.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: LGVN is currently unprofitable.

Growing Profit Margin: LGVN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: LGVN is unprofitable, and losses have increased over the past 5 years at a rate of 45.8% per year.

Accelerating Growth: Unable to compare LGVN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LGVN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).


Return on Equity

High ROE: LGVN has a negative Return on Equity (-61.46%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Longeveron's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: LGVN's short term assets ($28.2M) exceed its short term liabilities ($3.6M).

Long Term Liabilities: LGVN's short term assets ($28.2M) exceed its long term liabilities ($2.3M).


Debt to Equity History and Analysis

Debt Level: LGVN is debt free.

Reducing Debt: LGVN had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LGVN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: LGVN has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 40.3% each year.


Discover healthy companies

Dividend

What is Longeveron current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate LGVN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LGVN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LGVN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LGVN's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as LGVN has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Chris Min (55 yo)

0.25yr

Tenure

Dr. Kwan-Hong Min, also known as Christopher & Chris, MD, PhD, serves as Chief Medical Officer of Longeveron Inc. from April 04, 2022 and also serves as its Interim Chief Executive Officer since June 01, 2...


Leadership Team

Experienced Management: LGVN's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

Experienced Board: LGVN's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

NasdaqCM:LGVN Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
03 Jun 22SellUS$305,248James ClavijoIndividual36,955US$8.26
24 May 22SellUS$152,635Rock SofferIndividual19,500US$8.06
13 Oct 21BuyUS$72,855Rock SofferIndividual19,900US$3.76
13 Oct 21BuyUS$3,810Geoff GreenIndividual1,000US$3.81
12 Oct 21BuyUS$9,225Joshua HareIndividual2,500US$3.69
08 Oct 21BuyUS$16,930Joshua HareIndividual5,000US$3.39
07 Oct 21BuyUS$5,845Paul LehrIndividual1,750US$3.34
07 Oct 21BuyUS$16,700James ClavijoIndividual5,000US$3.34

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.8%.


Top Shareholders

Top 25 shareholders own 76.74% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
37.92%
Joshua Hare
7,958,497$32.2m0.54%no data
31.87%
Donald Soffer
6,688,737$27.0m-15.65%no data
3.2%
Rock Soffer
672,351$2.7m1231.2%no data
0.83%
The Vanguard Group, Inc.
173,667$701.6k49.89%no data
0.71%
Paul Lehr
149,949$605.8k-1.07%no data
0.52%
BlackRock, Inc.
109,999$444.4k32.55%no data
0.42%
Geoff Green
88,755$358.6k7.93%no data
0.37%
James Clavijo
78,193$315.9k-1.79%no data
0.28%
Neil Hare
58,514$236.4k2.18%no data
0.17%
Geode Capital Management, LLC
35,718$144.3k5.25%no data
0.085%
Erin Borger
17,836$72.1k-17.37%no data
0.071%
State Street Global Advisors, Inc.
14,800$59.8k0%no data
0.069%
Townsquare Capital, LLC
14,450$58.4k0%no data
0.067%
Schonfeld Strategic Advisors LLC
14,100$57.0k-92.52%no data
0.051%
Northern Trust Global Investments
10,623$42.9k0%no data
0.018%
Cathy Ross
3,750$15.2k0%no data
0.018%
Douglas Losordo
3,750$15.2k0%no data
0.012%
Ursula Ungaro
2,500$10.1k0%no data
0.012%
Todd Girolamo
2,500$10.1k0%no data
0.0095%
Securities America Advisors, Inc.
2,000$8.1k0%no data
0.0062%
Morgan Stanley, Investment Banking and Brokerage Investments
1,300$5.3k-3.7%no data
0.0056%
Kwan-Hong Min
1,168$4.7k0%no data
0.0043%
Global Vision Communications, LLC
894$3.6k0%no data
0.004%
Lord, Abbett & Co. LLC
830$3.4k0%no data
0.003%
Tower Research Capital LLC
631$2.5k0%no data

Company Information

Longeveron Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Longeveron Inc.
  • Ticker: LGVN
  • Exchange: NasdaqCM
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$84.788m
  • Shares outstanding: 20.99m
  • Website: https://www.longeveron.com

Number of Employees


Location

  • Longeveron Inc.
  • 1951 NW 7th Avenue
  • Suite 520
  • Miami
  • Florida
  • 33136
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LGVNNasdaqCM (Nasdaq Capital Market)YesClass A Common StockUSUSDFeb 2021

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/23 00:00
End of Day Share Price2022/09/23 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.